Trastuzumab rezetecan plus camrelizumab before surgery for HER2-positive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether giving a combination of two drugs before and after surgery can help people with HER2-positive bladder cancer that has grown into the bladder muscle. The goal is to see if this approach can shrink or control the cancer before the bladder is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have bladder cancer that has grown into the muscle layer (called muscle-invasive bladder cancer) and is HER2-positive.
- Your cancer must be removable with surgery (radical cystectomy).
- You must be in good enough health to have surgery and receive the study drugs.
- You must not have had prior cancer treatment for this bladder cancer, including chemotherapy, immunotherapy, or targeted therapy.
- You must agree to use effective birth control during the study and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, trastuzumab rezetecan and adebrelimab, given before surgery for a type of bladder cancer that has grown into the muscle. The goal is to see if this combination can shrink the tumor and improve outcomes for patients whose cancer cells have a certain protein called HER2.
This trial tests a combination of two drugs (trastuzumab rezetecan and adebrelimab) plus radiation to the bladder, aiming to preserve the bladder instead of removing it. It's for people with muscle-invasive bladder cancer that shows a specific marker called HER2.
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
This trial tests a combination of two drugs (eribulin and toripalimab) given before surgery to remove bladder cancer. The goal is to shrink the tumor and improve outcomes for people with advanced or high-risk bladder cancer.
This study tests a combination of two chemotherapy drugs and an immunotherapy drug given before and after surgery to remove the bladder. It aims to see if this treatment is safe and well-tolerated in patients with muscle-invasive bladder cancer.
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
Hear when a new Urinary Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.